ArticleClinical lung cancer2022

Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.

Andreas Rimner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.